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Background: Porous silicon particles (PSiPs) have been used extensively as drug delivery systems, loaded with
chemical species for disease treatment. It is well known from silicon producers that silicon is characterized by a low
reduction potential, which in the case of PSiPs promotes explosive oxidation reactions with energy yields exceeding
that of trinitrotoluene (TNT). The functionalization of the silica layer with sugars prevents its solubilization, while
further functionalization with an appropriate antibody enables increased bioaccumulation inside selected cells.
Results: We present here an immunotherapy approach for potential cancer treatment. Our platform comprises the
use of engineered silicon particles conjugated with a selective antibody. The conceptual advantage of our system is
that after reaction, the particles are degraded into soluble and excretable biocomponents.
Conclusions: In our study, we demonstrate in particular, specific targeting and destruction of cancer cells in vitro.
The fact that the LD50 value of PSiPs-HER-2 for tumor cells was 15-fold lower than the LD50 value for control cells
demonstrates very high in vitro specificity. This is the first important step on a long road towards the design and
development of novel chemotherapeutic agents against cancer in general, and breast cancer in particular.Background
Cancer is the second cause of death worldwide. In the
case of breast cancer, epidemiological studies point to
more than one million new cases diagnosed per year and
an annual mortality rate close to 450,000 deaths. Parti-
cles have shown great potential [1] for drug delivery
[2-4] and cancer treatment [5-8]. In most approaches,
particles are directed to target cells by antibodies at-
tached to their surfaces, which in the case of in vivo ad-
ministration, supplements passive targeting through the
EPR (enhanced permeability and retention) effect [9].
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unless otherwise stated.causing apoptosis of the nearby cells through magne-
tothermia [10,11] or photothermia [6,12-15]. These ma-
terials suffer certain limitations, such as the large and
expensive facilities (i.e. magnetic resonance imaging, MRI)
necessary for magnetothermia, and the limited penetration
depth of light in the body in the case of photothermia.
Other approaches make use of antibody functionalized
particles loaded with cancer drugs to deliver the drug to
tumor cells [5,16-19]. Porous silicon particles (PSiPs) have
been considered a very promising platform for cancer
therapy because of their excellent biocompatibility [20]
and biodegradability [5,21-23]. In all studies reported to
date, PSiPs work either as a passive carrier of an antican-
cer cargo [5,16-19] or as an element activated by an ap-
propriate trigger, namely light and acoustic waves for
particle thermalization [14,24,25] or singlet oxygen gener-
ation in photodynamic therapies [8]. Here, we demon-
strate that PSiPs themselves can be used as a drug for
cancer treatment and how to modulate their activity by
taking advantage of their surface functionalization and the
enzymatic machinery of eukaryotic cells.ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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of −1.697 eV to yield silicates or −0.91 eV to yield silica,
which is ultimately dissolved as silicates in the presence of
water. The low reduction potential makes the reactions
violent and even explosive [27] in nanoscaled porous par-
ticles [28]. On the other hand, the high tendency of silicon
to undergo oxidation is modulated by the spontaneous
generation of a passivation layer of SiOx when exposed to
open atmosphere. Notably, this passivation layer dissolves
in water and particularly in slightly acidic media. The kin-
etics of the dissolution of this layer can be modulated by
surface functionalization of the silica. Thus, by coating
with a compact monolayer of an organic molecule, dissol-
ution can be retarded or even prevented.
The processes for obtaining PSiPs have been well known
for 20 years [29]. They are mainly based on wet chemistry
methods, where the starting material, bulk silicon, is
converted into porous silicon, by an electrochemical or
stain-etching reaction, followed by a process such as
ultrasonication, to break the porous layer into small parti-
cles [30,31]. Other, less studied methods, use a bottom-up
approach based on chemical vapor deposition techniques,
where the starting material is a precursor gas, namely si-
lane or di-silane, which can be decomposed at high tem-
peratures [26]. Under controlled conditions of pressure,
temperature and time, such gases nucleate and nano-
metric porous silicon particles can be obtained [32]. This
is a complex process, and the involved mechanisms are
still under study (see Methods) [33,34]. In some manner
PSiPs can be regarded as a macromolecule resulting from
the polymerization of disilane with a dramatic capability
of oxidation.
Herein we demonstrate that silicon particles coated
with a native silica layer can be engineered with the bio-
organic appropriate ligands to target and accumulate
into tumour cells. Once inside the cell, the particles are
driven to the lysosome were the enzymatic machinery
of the cell metabolize the ligands. Then, the exposition
of the soluble silica coating to the aqueous lysosomal
solution degrades this layer allowing water to react vio-
lently with the silicon. As result the target cells dye
while the particles are degraded into soluble and excre-
table biocomponents.
Results and discussion
Our process to obtain the particles used in this work
stem from these methods [35]. The nanostructured par-
ticles were highly spherical with a diameter between 1.5
and 2 μm, with an intrinsic photoluminescence in be-
tween the dark red and the near infrared (Figure 1A and
B) [36]. As prepared, and after extracting the materials
from the reactor, exposure to atmospheric oxygen gener-
ated a thin layer of silicon oxide (Figure 2C and D). This
coating acted as a protective shell and generated aneasily functionalizable surface to couple an organic layer
would protect the silica from dissolution in physiological
media. The enzymatic machinery present in the cell can
easily degrade this protective organic shell, which would
consequently trigger oxidation reactions of the particles
after their internalization by cells. To prove this concept,
we used a glucopyranoside derivative that can be easily me-
tabolized by the lysosomal enzyme α-D-glucoside glucohy-
drolase. The lysosome has been shown to be a target
organelle for most nano- and microparticles [37,38] and
thus it can be predicted that after internalization by cells,
the particles would be exposed to α-D-glucoside
glucohydrolase.
The sugar and the particle cannot be directly linked with-
out previous modifications. Thus, PSiPs were capped with
aminopropylsilane (APS) [39], while the glucopyranoside
selected was 2-acetamido-2-deoxy-β-D-glucopyranosylox-
yacetic acid (Figure 2, see Methods and SI for details). The
benzotriazol-1-yloxytris(dimethylamino)phosphonium hex-
afluorophosphate/anhydrous 1-hydroxybenzotriazole (BOP/
HOBt) coupling method was chosen to generate a peptide
bond between the amine-functionalized particle surface and
the carboxylic acid group attached to the carbohydrate.
Notably, within this configuration, hybrid particles will re-
sist oxidation in physiological media but should be de-
graded unselectively within any cell, following endocytosis
and subsequent localization within the lysosome. Therefore,
for anticancer therapy, a selective antibody that targets the
surface receptor of the desired cell is necessary.
Consequently, the third step in the preparation of our
immunotherapeutic material involved the coupling of a
directing vector. HER-2-positive breast cancer is charac-
terized by the amplification of this gene and high expres-
sion and activity of its protein [40]. In fact, there is a
strong association between HER-2 (ErbB2) tyrosine kin-
ase expression and the aggressiveness and prognosis of
the disease. Fortunately, HER-2 amplification confers a
selective target for specific treatment and several drugs
targeting his receptor are actually used for breast cancer
treatment in medical practice, including small molecule
tyrosine kinase inhibitors (TKIs) such as gefitinib, erloti-
nib or lapatinib or monoclonal antibodies such as trastu-
zumab, pertuzumab or cetuximab [41]. HER-2 is also a
standard receptor for specific targeting [42]. For our mate-
rials, rather than using standard carbodiimide chemistry,
the HER-2 antibody was linked to the particles by taking
advantage of its affinity for the sugar. Thus, one of the four
glycosylation immunogenic regions was spontaneously
coupled to the sugars present on the particle surface,
allowing the other three to interact with the cell membrane
receptors [43].
First, to test the interaction of our particles with the
cells, the PSiP-HER-2 were internalized by the HER-2
positive cell line, SK-BR-3. The particles could be
Figure 1 Silicon particle characterization. (A) SEM and optical microscopy images of the porous silicon particles as prepared and (B) their size
distribution. All scale bars in the insets correspond to 2 μm. (C) SEM image of a porous silicon colloid carved using the focused ion beam (FIB)
technique. (D) EDX analysis of materials inside a silicon colloid as a function of the distance from the sphere center, normalized to the sphere
radius (d = distance from the sphere center/sphere radius). The graph shows the counts for the Si and O peaks of the EDX spectra at five different
points of analysis. The points were selected along a line travelling from the nucleus (d = 0) to the sphere surface (d = 1).
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Some particles remained in the extracellular space,
while other particles were seen attached to the cell
membrane. Despite their micro-size and the degree of
agglomeration, the particles could be internalized by
SK-BR-3 cells without affecting their viability at an early
stage. This is in agreement with other work [37] show-
ing that particles at the micro-scale can be safely incor-
porated by eukaryotic cells.
Next, we tested the efficiency of the PSiPs functional-
ized with antibodies against HER-2 receptors (PSiPs-
HER-2) for their potential to selectively kill only cells
overexpressing HER-2. To this end, we used two differ-
ent cell lines, one overexpressing the HER-2 receptor
(SK-BR-3) and one with its normal expression level
(MDA-MB-435) [44]. The cells were seeded in 96-well
plates and incubated with different quantities of PSiPs-
HER-2 for 48 h, before a resazurin-based viability assay
was performed. Resazurin is a nonfluorescent molecule
that is reduced by metabolic active cells to thefluorescent resorufin. Thus, the number of viable cells
can be determined by measuring resorufin fluorescence.
Notably, when SK-BR-3 cells (cells overexpressing the
HER-2 receptors) were treated with PSiPs-HER-2, their
viability was clearly compromised (Figure 4, black points).
On the other hand SK-BR-3 cells treated with PSiPs (Fig-
ure 4, blue points) or MDA-MB-435 cells treated with
PSiPs or PSiPs-HER-2 (Figure 4, red and green points, re-
spectively) showed a more delayed toxicological response.
The LD50 (lethal dose killing 50% of the cell population)
values are presented in Table 1. Only around 250 μg/mL
PSiPs-HER-2 were needed to kill 50% of the SK-BR-3 cells,
whereas much higher quantities of the same particles were
required under the same conditions to kill the same pro-
portion of MDA-MB-435 cells. On the other hand, PSiPs
without attached HER-2 antibodies showed a much lower
toxicological response, as their LD50 values were very high
for both cell types.
These results confirm the efficacy of PSiPs-HER-2 to
recognize the HER-2 receptors present on the surface of
Figure 3 Particle localization into SK-BR-3 cell lines. SK-BR-3 (cell membrane labeled in blue) treated with PSiP-HER-2 particles (presented in
green) for 24 h, showing the particles inside (arrow) and, outside (dashed arrow) the cells and at the cell membrane (opened arrow). (A) Orthogonal
view in the 3 planes (X/Y, X/Z and Y/Z) of the particles pointed at the intersection of the X and Y axeis. As seen from all planes, the particles are
surrounded by the cell membrane. (B) Confocal images of the cells in the transmission channel, the cell membrane and PSiP-HER-2 in fluorescent
channels, and overlay of all channels. PSiP-HER-2 were labeled with DyLight 488.
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Figure 2 Synthesis and derivatization of the glucopyranose derivative, and the antibody coupling to the particles.
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Figure 4 Cell viability. Relative cell viability after incubation of SK-BR-3 and MDA-MB-435 cells with PSiPs and PSiPs-HER-2 for 48 h.
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435 cells and to effectively promote their local accumu-
lation. The degree of targeting was more than sufficient
to accelerate the death of the targeted cancer cells.Conclusions
In summary, we present here an immunotherapy ap-
proach for potential cancer treatment. Our platform
comprises the use of engineered silicon particles conju-
gated with a selective antibody. The conceptual advan-
tage of our system is that after reaction, the particles are
degraded into soluble and excretable biocomponents. In
our study, we demonstrate in particular, specific target-
ing and destruction of cancer cells in vitro. The fact that
the LD50 value of PSiPs-HER-2 for tumor cells was 15-
fold lower than the LD50 value for control cells demon-
strates very high in vitro specificity. This is the first im-
portant step on a long road towards the design andTable 1 Calculated LD50 obtained from the dose–response
curves shown in Figure 4
Cell line Type of NP LD50 (μg/mL) LD50 SD
SK-BR-3 PSiPs-HER-2 249 10
MDA-MB-435 PSiPs-HER-2 3776 180
SK-BR-3 PSiPs 5603 360
MDA-MB-435 PSiPs 2672 214development of novel chemotherapeutic agents against
cancer in general, and breast cancer in particular.Methods
Synthesis of porous silicon microspheres
Our method for producing porous silicon microspheres is
based on the decomposition of disilane gas (Si2H6) by
chemical vapor deposition (CVD). This is similar to the
synthesis of silicon colloids [45], where the gas is intro-
duced in a reactor whose walls are heated at high tempera-
tures for a certain time, usually higher than 400°C. During
this procedure, SinHm clusters grow in the gas phase [46]
and these become highly spherical, micrometer-sized parti-
cles, through surface tension forces. At the same time, the
process of hydrogen desorption from the clusters progres-
sively reduces the hydrogen content until they become hy-
drogenated amorphous silicon (a:Si-H) colloids. To obtain
porous silicon microspheres, the heating process is stopped
at an early stage, before the formation of amorphous sili-
con colloids is complete. In this way, porous particles with
an undetermined composition of silicon and hydrogen
atoms are obtained.
Porous silicon particles for this work were synthesized
using a di-silane decomposition temperature of 400°C.
The absolute gas pressure in the reactor was about
0.25 atm at room temperature and we used decomposition
times from 1 to 2 minutes, measured from the stage where
the gas reaches the target temperature.
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were analyzed by electron dispersive X-ray (EDX) mea-
surements. For this purpose, colloids were carved using
a focus ion beam (FIB) technique (FEI Helios NanoLab
Omniprobe). Figure 1C shows a scanning electron micro-
scope (SEM) image of a carved colloid, 1.2 μm in diam-
eter. The carved surface appears to be flat because the ion
gun of the FIB removes material and deposits it at the
same time on the surface of the particle, thus hiding por-
ous structures. Nevertheless, because the EDX interaction
volume penetrates the region where pores are less modi-
fied by the FIB carving action, one can extract useful infor-
mation about the cavity structure. Figure 1D shows the
EDX analysis corresponding to silicon and oxygen in dif-
ferent regions of the particle, from the cavity center to the
cavity surface. This shows two key results: a) the oxygen
content appears to be completely within the cavity and b)
the oxygen (silicon) concentration increases (decreases)
from the center to the surface. This result supports the hy-
pothesis that porous silicon colloids possess a gradient, or
onion-like, porous structure, as images taken by optical
microscopy suggest. In addition, it indicates that porosity
is higher at the surface of the colloid than within it.
Synthesis of the 2-acetamido-2-deoxy-β-d-glucopyranosy-
loxyacetic acid
Solvents were dried according to published methods and
distilled before use. All other reagents were commercial
compounds of the highest purity available. Unless otherwise
indicated, all reactions involving air- and moisture-sensitive
materials were carried out under an argon atmosphere,
while those not involving aqueous reagents were carried
out in oven-dried glassware. Analytical thin layer chroma-
tography (TLC) was performed on aluminum plates with
Merck Kieselgel 60 F254 and visualized by UV irradiation
(254 nm) or by staining with an ethanolic solution of phos-
phomolybdic acid. Flash column chromatography was car-
ried out using Merck Kieselgel 60 (230–400 mesh) under
pressure. 1H NMR spectra were recorded in CDCl3 and
D2O, at ambient temperature on an AMX-400 spectrom-
eter at 400 MHz, with residual protic solvent as the in-
ternal reference [CDCl3, δH = 7.26 ppm]; chemical shifts
(δ) are given in parts per million, and coupling constants
(J) are given in Hertz. The proton spectra are reported
as follows: δ (multiplicity, coupling constant J, number of
protons, assignment).
2-(Benzyloxy)ethanol 2. To a mixture of NaH (3.4 g,
0.085 mol, 60% w/w in mineral oil) in tetrahydrofuran(THF, 150 mL), ethylene glycol 1 (25.1 mL, 0.45 mol)
was added and the mixture was stirred for 1 h at 25°C.
Then, benzyl bromide (8.9 g, 0.075 mol) was added and
the reaction was refluxed for 12 h. After cooling the
mixture (0°C), a saturated aqueous solution of NH4Cl
was added, the solvent was evaporated and the mixture
was extracted with EtOAc (3×). The combined organic
layers were washed with a saturated aqueous solution of
NH4Cl and brine, and dried (Na2SO4). The solvent was
evaporated to afford 11.22 g (98% yield) of a colorless oil
identified as 2-(benzyloxy)ethanol 2. The spectroscopic
data were identical to those described in the literature
[47]. 1H-NMR (400 MHz, CDCl3): δ 7.40-7.30 (m, 5H),
4.58 (s, 2H), 3.78 (t, J = 5.0 Hz, 2H), 3.61 (t, J = 4.9 Hz,
2H), 2.06 (br, 1H, OH) ppm.
1,3,4,6-tetra-O-acetyl-α/β-N-acetylglucosamine 4. N-acetyl-
D-glucosamine 3 (5 g, 22.6 mmol) was dissolved in pyri-
dine (36 mL) and acetic anhydride (25 mL) was added
dropwise at 0°C. The reaction mixture was stirred at 25°C
for 24 h, then diluted with CH2Cl2 and washed consecu-
tively with cold water, a saturated aqueous solution of
NaHCO3, and a 10% aqueous solution of CuSO4. The or-
ganic layer was dried (Na2SO4) and the solvent was evapo-
rated to obtain 6.60 g (75%) of a white solid identified as
1,3,4,6-tetra-O-acetyl-α/β-N-acetylglucosamine 4. The spec-
troscopic data were identical to those described in the
literature [48]. 1H-NMR (400 MHz, CDCl3): δ 6.17 (d,
J = 3.6 Hz, 1H), 5.64 (d, J = 9.3 Hz, 1H), 5.30-5.20 (m, 2H),
4.49 (ddd, J = 10.6, 8.9, 3.6 Hz, 1H), 4.25 (dd, J = 12.5,
4.1 Hz, 1H), 4.07 (dd, J = 12.5, 2.4 Hz, 1H), 4.00 (ddd,
J = 9.6, 4.0, 2.3 Hz, 1H), 2.20 (s, 3H), 2.09 (s, 3H), 2.06
(s, 3H), 2.05 (s, 3H), 1.94 (s, 3H) ppm.
4′,5′-Dihydro-2′-methyloxazolo [5′,4′:1,2]-3,4,6-tri-O-
acetyl-1,2-dideoxy-α-D-glucopyranoside 5. To a solution
of 1,3,4,6-tetra-O-acetyl-α/β-N-acetylglucosamine 4 (2.49 g,
6.4 mmol) in dichloroethane (25 mL) TMSOTf (1.8 mL,
9.6 mmol) was added and the reaction was stirred for 2 h
at 55°C and for 12 h at 25°C. A saturated aqueous solution
of NaHCO3 was added and the mixture was extracted with
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with a saturated aqueous solution of NaHCO3 and dried
(Na2SO4) and the solvent was evaporated. The resulting
residue was purified by column chromatography (silica gel,
97:3 CH2Cl2/MeOH) to afford 1.86 g (78%) of 4′,5′-dihydro-
2′-methyloxazolo [5′,4′:1,2]-3,4,6-tri-O-acetyl-1,2-dideoxy-α-
D-glucopyranoside 5. The spectroscopic data were identical
to those described in the literature [49]. 1H-NMR (400 MHz,
CDCl3): δ 5.98 (d, J= 7.4 Hz, 1H), 5.27 (t, J= 2.4 Hz, 1H),
4.94 (ddd, J = 9.2, 2.0, 1.2 Hz, 1H), 4.19-4.14 (m, 3H), 3.62
(dt, J= 8.8, 4.3 Hz, 1H), 2.12 Hz (s, 3H), 2.11 (s, 3H), 2.10
(s, 3H), 2.09 (s, 3H) ppm.
2-Hydroxyethyl-2-acetamido-3,4,6-tri-O-acetyl-2-deox
y-β-D-glucopyranoside 7. 10-(R)-camphorsulfonic acid
(1.40 g, 5.02 mmol) and 2-(benzyloxy)ethanol 2 (7.63 g,
50.2 mmol) were added to a stirred solution of 4′, 5′-
dihydro-2′-methyloxazolo [5′,4′:1,2]-3,4,6-tri-O-acetyl-
1,2-dideoxy-α-D-glucopyranoside 5 (1.86 g, 5.02 mmol)
and powdered 4 Å molecular sieves (ca. 8 g) in CH2Cl2
(30 mL) and the reaction was stirred at 40°C for 14 h.
The mixture was cooled to 0°C and a saturated aqueous
solution of NaHCO3 (60 mL) and CH2Cl2 (30 mL)
was added. The layers were separated and the organic
layer was washed with a saturated aqueous solution of
NaHCO3, brine and dried (Na2SO4), and the solvent then
evaporated. The residue was purified by column chroma-
tography (hexane/EtOAc 50:50 to CH2Cl2/MeOH 95:5)
providing 2-O-benzyloxyethyl-2-acetamido-3,4,6-tri-O-acetyl-
2-deoxy-β-D-glucopyranoside 6 as a colorless solid. The spec-
troscopic data of the product were identical to those
described in the literature [50]. 1H-NMR (400 MHz,
CDCl3): δ 7.4-7.3 (m, 5H), 5.50 (d, J = 8.8 Hz, 1H), 5.25 (dd,
J = 10.4, 9.4 Hz, 1H), 5.09 (t, J = 9.6 Hz, 1H), 4.76 (d,
J = 8.4 Hz, 1H), 4.56 (app s, 2H), 4.27 (dd, J = 12.3, 4.7 Hz,
1H), 4.20-4.15 (m, 2H), 3.99 (dt, J = 11.5, 3.9 Hz, 1H), 3.80
(ddd, J = 18.2, 14.7, 11.2 Hz, 1H), 3.70-3.65 (m, 3H), 2.09 (s,
3H), 2.06 (s, 3H), 2.03 (s, 3H), 1.87 (s, 3H) ppm.
A mixture of 2-O-benzyloxyethyl-2-acetamido-3,4,6-tri-O-
acetyl-2-deoxy-β-D-glucopyranoside 6 (0.19 g, 0.36 mmol)
and Pd/C (10%, 0.02 g) in MeOH (3 mL) was stirred under
an H2 atmosphere for 7 h at 25°C. The reaction was fil-
tered through Celite and the solvent was evaporated to
afford 0.15 g (96%) of a solid identified as 2-hydroxyethyl-
2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-D-glucopyranoside7. The spectroscopic data of the product were identical to
those described in the literature [50]. 1H-NMR (400 MHz,
CDCl3): δ 5.58 (d, J= 9.0 Hz, 1H), 5.25 (dd, J= 10.6, 9.4 Hz,
1H), 5.07 (t, J= 9.6 Hz, 1H), 4.71 (d, J= 8.3 Hz, 1H), 4.2-4.10
(m, 2H), 3.9-3.8 (m, 2H), 3.7-3.6 (m, 2H), 2.58 (br, 1H, OH),
2.11 (s, 3H), 2.06 (s, 3H), 2.05 (s, 3H), 1.98 (s, 3H) ppm.
2-Acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-D-glucopyr-
anosyloxyacetic acid 8. Jones reagent (3.5 M, 0.2 mL,
0.69 mmol) was added to a stirred solution of 2-
hydroxyethyl-2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-D-
glucopyranoside 7 (0.15 g, 0.35 mmol) in acetone (2 mL)
at 0°C and the reaction was stirred for 13 h at 25°C. Iso-
propanol was added and the solvent was evaporated. After
the addition of CH2Cl2 (10 mL) and brine (10 mL), the
layers were separated, the organic layer was washed with
brine and dried (Na2SO4), and the solvent was evaporated
to afford 0.11 g (73%) of a white solid that was identified
as 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-D-glucopyra-
nosyloxyacetic acid 8 The spectroscopic data of the prod-
uct were identical to those described in the literature [50].
1H-NMR (400 MHz, CDCl3): δ 6.57 (br s, 1H), 5.22 (t,
J = 9.6 Hz, 1H), 5.11 (t, J = 9.6 Hz, 1H), 4.75 (d, J = 8.1 Hz,
1H), 4.35 (app s, 2H), 4.28 (dd, J = 12.1, 4.9 Hz, 1H), 4.15
(dd, J = 10.7, 2.1 Hz, 1H), 4.1-4.0 (m, 1H), 3.7-3.6 (m, 1H),
2.11 (s, 3H), 2.06 (s, 3H), 2.03 (s, 3H), 1.97 (s, 3H) ppm.
2-Acetamido-2-deoxy-β-D-glucopyranosyloxyacetic Acid
9. Sodium methoxide (0.02 g, 0.332 mmol) was added to a
stirred solution of 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-
β-D-glucopyranosyloxyacetic acid 8 (0.114 g, 0.255 mmol)
in MeOH (6 mL) and the reaction mixture was stirred at
25°C for 24 h. After the addition of Dowex-200 the mixture
was filtered and the solvent was evaporated. The residue
was dissolved in H2O and dried under vacuum to afford
0.071 g (99%) of a solid identified as 2-acetamido-2-deoxy-
β -D-glucopyranosyloxyacetic acid 9. The spectroscopic
data of the product were identical to those described in
the literature [50]. 1H-NMR (400 MHz, D2O): δ 4.49 (d,
J = 8.4 Hz, 1H), 4.18 (s, 2H), 3.83 (d, J = 12.2 Hz, 1H),
3.70-3.60 (m, 2H), 3.50-3.40 (m, 1H), 3.40-3.30 (m, 2H),
1.97 (s, 3H) ppm.
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A suspension of aminopropylsilane (APS)-coated silicon
particles was produced by treatment of 0.1 g silica parti-
cles with APS (20 μL) in 2-propanol (5 mL) at 80°C for
2 h. The particles were centrifuged at 3800 rpm for
30 min to remove the excess APS, followed by replace-
ment of the supernatant solution by isopropanol. The
particles were re-dispersed by shaking (ultrasound) for
10 min. This protocol was repeated two more times [51].
The particles were centrifuged at 3800 rpm for 30 min
and the supernatant was replaced by dimethylformamine
(DMF). Then, a solution of 2-acetamido-2-deoxy-β-D-glu-
copyranosyloxyacetic acid 9 (14 mg), benzotriazol-1-yloxy)
tris(dimethylamino)phosphonium hexafluorophosphate (BOP,
29 mg), hydroxybenzotriazole (HOBt, 7 mg) in DMF (3 mL)
and diisopropylethylamine (30 μL) were added and the sus-
pension was stirred for 12 h at 25°C. The particles were cen-
trifuged at 3800 rpm for 30 min, washed with DMF and the
supernatant then replaced by H2O. The particles were re-
dispersed by shaking (ultrasound) for 10 min. The super-
natant was replaced by phosphate buffered saline (PBS, 1×).
To a suspension of the particles in PBS (2 mL) 250 μL
of a solution of anti-erbB-2/HER-2 (1 μL/L in PBS) was
added and the mixture was shaken at 0°C for 12 h. The
particles were centrifuged at 3800 rpm for 10 min, and the
supernatant was replaced with PBS. The particles were re-
dispersed by shaking (ultrasound) for 3 min at 0°C.
Cell culture and viability assay
Materials: Dulbecco’s modified eagle’s medium (DMEM, #30-
2002) and McCoy’s 5a medium (#30-2007) were purchased
from ATCC. Fetal bovine serum (FBS, #S0615) was obtained
from Biochrom AG and penicillin/streptomycin (#15140-122)
from Gibco (#15140-122). L-glutamine (#25030-024) was
purchased from Life Technologies. The viability assay based
on Resazurin (#TOX8) and the 96-well plates (#CLS3603)
in which the viability assay was carried out were obtained
from Sigma-Aldrich (St Louis, MO, USA).
MDA-MB-435 human epithelial cells (ATCC #HTB-129)
were seeded and grown in growth medium (DMEM with
4.5 g/L glucose supplemented with 10% FBS, 1% L-glutamine
(200 mM) and 1% penicillin/streptomycin. SK-BR-3 hu-
man breast adenocarcinoma cells (ATCC #HTB-30) were
seeded and grown in another growth medium (McCoy’s
medium supplemented with 10% FBS, 1% L-glutamine
(200 mM) and 1% penicillin/streptomycin.
Imaging of the particle internalization: SK-BR-3 cells
were seeded on an Ibidi 8-well plate (2E4 cells/well) and
left to adhere and grow for 4 days. Subsequently, the cells
were incubated with 30 μg/mL PSiP-HER-2 particles for
24 h. The cells were then washed intensively and the cell
membrane stained with 20 μg/mL cell mask deep red for
10 min at 37°C before imaging. Images of living cells using
transmitted and reflected light were taken with a confocallaser scanning microscope (NIKON TE2000-E). A 650
LP filter was used to collect the fluorescence signal of
the cell membrane after excitation at 633 nm, whereas a
515/30 BP filter was used to collect the light reflected
by the DyLight 488 labeled PSiP-HER-2 after irradiation
with a 488 nm laser line. As previously reported, the
particles exhibit intrinsic photoluminescence because of
the presence of the microcavities [35,36].
Viability assay: 20,000 cells (MDA-MB-435 or SK-BR-3)
were seeded per well in a 96-well plate and incubated in
100 μL of the corresponding cell medium for 48 h at 37°C
and 5% CO2. After this time, different concentrations of
particles (PSiNPs or PSiNPs-HER-2) were added and cells
were incubated for another 48 h. The viability assay was
repeated three times at each concentration. Control viabil-
ity assays were performed using cells without particles and
particles without cells. After incubation, cellular viability
was probed. Cells were washed with PBS and a solution of
10% of resazurin in growth medium was added to each
well. Cells were placed in the incubator for 3 h (37°C and
5% CO2). Resazurin is a nonfluorescent molecule that is
reduced from the oxidized to the reduced form, resofurin,
by metabolically active cells. Resofurin is fluorescent, has a
maximum emission wavelength at 585 nm (red emission),
and can be excited from 530 to 560 nm. The fluorescent
emission intensity originating from resofurin is propor-
tional to the number of metabolically active (=living) cells.
Fluorescence emission was measured with a Fluorolog-3
spectrofluorometer equipped with a microwell plate reader
(MicroMax 384) from Horiba JOBIN YVON. The samples
were excited at 560 nm and the emission spectra were col-
lected from 572 to 650 nm. Background was subtracted
from the spectra. As the position of the maximum emis-
sion, wavelength can be slightly shifted, so the peak emis-
sion was averaged from 584 to 586 nm. The emission peak
intensity values were normalized, considering a cell viability
of 100% for the control experiments, in which no particles
had been added to the cells. The normalized fluorescence
emission peak intensities were plotted against the logarithm
of the particle concentration, cf. Figure 4. Dose–response
curves were obtained for SK-BR-3 and MDA-MB-435 ex-
posed to different concentrations of Si-NPs and SiNPs-
HER2, cf. Figure 4. The results were fitted to sigmoidal
curves and the inflexion point was calculated. The inflex-
ion point represents the LD50 value, which in this case is
the concentration of particles at which cell viability is re-
duced to 50%, i.e. 50% of the cells are no longer metabolic-
ally active. The calculated LD50 values are shown in Table 1.
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